AR061230A1 - Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa - Google Patents

Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa

Info

Publication number
AR061230A1
AR061230A1 ARP070102413A ARP070102413A AR061230A1 AR 061230 A1 AR061230 A1 AR 061230A1 AR P070102413 A ARP070102413 A AR P070102413A AR P070102413 A ARP070102413 A AR P070102413A AR 061230 A1 AR061230 A1 AR 061230A1
Authority
AR
Argentina
Prior art keywords
egf
tgf
survival
cancer
alfa
Prior art date
Application number
ARP070102413A
Other languages
English (en)
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of AR061230A1 publication Critical patent/AR061230A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Prolongacion de la supervivencia de un paciente con cáncer, donde el paciente produce un nivel elevado de EGF o TGF-alfa, tratando al paciente con un inhibidor de dimerizacion de HER, como pertuzumab.
ARP070102413A 2006-06-05 2007-06-05 Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa AR061230A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81123406P 2006-06-05 2006-06-05

Publications (1)

Publication Number Publication Date
AR061230A1 true AR061230A1 (es) 2008-08-13

Family

ID=38691718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102413A AR061230A1 (es) 2006-06-05 2007-06-05 Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa

Country Status (13)

Country Link
US (1) US20080038271A1 (es)
EP (1) EP2035039A2 (es)
JP (1) JP2009539836A (es)
KR (1) KR20090019890A (es)
CN (1) CN101495142A (es)
AR (1) AR061230A1 (es)
AU (1) AU2007259171A1 (es)
BR (1) BRPI0712077A2 (es)
CA (1) CA2654584A1 (es)
CL (1) CL2007001602A1 (es)
MX (1) MX2008015581A (es)
TW (1) TW200815472A (es)
WO (1) WO2007145862A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2003534292A (ja) * 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
US7560111B2 (en) * 2004-07-22 2009-07-14 Genentech, Inc. HER2 antibody composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
PT1850874E (pt) 2005-02-23 2013-12-02 Genentech Inc Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
EP3301446B1 (en) * 2009-02-11 2020-04-15 Caris MPI, Inc. Molecular profiling of tumors
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
EP2573175B1 (en) * 2010-05-18 2020-07-08 Medical and Biological Laboratories Co., Ltd. ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
WO2012010551A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
NZ712012A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
KR102313262B1 (ko) 2016-12-28 2021-10-14 제넨테크, 인크. 진행성 her2 발현 암의 치료
TWI729259B (zh) 2017-01-17 2021-06-01 美商建南德克公司 皮下her2 抗體調配物
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122014028365B8 (pt) * 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者

Also Published As

Publication number Publication date
US20080038271A1 (en) 2008-02-14
AU2007259171A1 (en) 2007-12-21
CA2654584A1 (en) 2007-12-21
CN101495142A (zh) 2009-07-29
KR20090019890A (ko) 2009-02-25
MX2008015581A (es) 2008-12-17
BRPI0712077A2 (pt) 2012-01-17
WO2007145862B1 (en) 2008-05-02
CL2007001602A1 (es) 2008-03-14
TW200815472A (en) 2008-04-01
WO2007145862A2 (en) 2007-12-21
WO2007145862A3 (en) 2008-02-28
EP2035039A2 (en) 2009-03-18
JP2009539836A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
AR061230A1 (es) Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
DOP2013000212A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
EA201171367A1 (ru) Винилиндазолильные соединения
MY163852A (en) Amidophenoxyindazoles useful as inhibitors of c-met.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
UY32551A (es) Compuestos peptidomiméticos de sulfamida y usos antivirales de los mismos
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
EA200802111A1 (ru) Имплантаты для лечения состояний, ассоциируемых с допамином
CO2022000481A2 (es) Inhibidores de enzimas
CY1114217T1 (el) Θεραπεια του μελανωματος
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
MX2009009693A (es) Metodos para activar irs-1 y akt.
CY1112443T1 (el) Νεα θεραπευτικη χρηση για τη θεραπεια των λευχαιμιων
ECSP099836A (es) Macrociclos y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure